Highlights

  • Pro Medicus (ASX:PME) delivered record FY26 revenue, profit growth and a higher dividend.
  • The company continues expanding its medical imaging software platform across healthcare markets.
  • Strong contract wins and recurring Revenue support the company’s Long-term Growth strategy.
  • Investor attention remains on growth sustainability, valuation and technological developments in healthcare software.

Medical imaging software company Pro Medicus (ASX:PME) continues strengthening its position in healthcare technology following an FY26 result that highlighted record revenue, strong profitability and significant contract momentum. The company provides imaging solutions to healthcare organisations, with its growth strategy centred on recurring revenue, technological capability and expansion across global markets.

FY26 Performance

Pro Medicus reported FY26 revenue of $261.7 million, representing growth of 22.9% and 28.4% on a constant-currency basis.

Net profit after tax increased 24.1% to $144.7 million, while the EBIT Margin reached 74.9%, highlighting the company’s highly scalable software Business model. The company also increased its Dividend by 25.5% to 69 cents per share, fully franked.

Contract Momentum

A key feature of Pro Medicus’ FY26 performance was continued strength in its contract pipeline.

The company secured a minimum of $407 million in new contracts and $141 million in combined renewed contracts, reinforcing the Demand for its medical imaging platform and the strength of its Recurring Revenue model.

These contract wins support the company’s long-term growth outlook while highlighting continued adoption among healthcare providers.

Healthcare Technology Opportunity

Pro Medicus operates within the growing healthcare technology sector, providing imaging software solutions used by major healthcare organisations.

The company’s platform generates recurring transaction-based revenue, supporting strong margins and predictable earnings. Continued adoption of digital healthcare solutions and demand for efficient imaging workflows remain important growth drivers.

Management Strategy

Management has continued focusing on expanding the company’s technology platform, strengthening customer relationships and maintaining its position within medical imaging software.

The company’s strategy centres on leveraging its technological capabilities, securing long-term contracts and expanding opportunities across healthcare markets.

Future Outlook

Key factors to monitor for Pro Medicus include new contract wins, implementation of signed agreements, revenue growth and expansion into adjacent healthcare technology opportunities.

Investors will also monitor developments in artificial intelligence and medical imaging, as technological changes could influence the competitive landscape. The FY27 half-year result will provide further insight into growth momentum and margin sustainability.

Key Risks

Pro Medicus faces risks associated with valuation expectations, as high-growth technology companies can be sensitive to changes in investor sentiment.

The company also faces competition and technological risks, including developments in artificial intelligence that could influence medical imaging solutions. Customer concentration, contract timing, foreign-exchange movements and healthcare procurement conditions remain additional considerations.

Conclusion

Pro Medicus (ASX:PME) delivered a strong FY26 performance, supported by record revenue of $261.7 million, a 24.1% increase in profit, exceptional margins and significant contract wins. The company continues benefiting from its high-margin medical imaging software model and recurring revenue base. Future performance will depend on maintaining growth momentum, expanding contract opportunities and sustaining its technological advantage within healthcare software.